Suppr超能文献

[雌激素受体、孕激素受体及人表皮生长因子受体2在乳腺癌中的表达及其意义:910例病例分析]

[Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].

作者信息

Liu Ren-bin, Zhou Xing-hua, Wang Jia-ni, Liang Hui-zhen, Li Xiao-xi, Wu Zhuang-hong, Ye Jie-lian, Wang Shen-ming

机构信息

Department of Breast Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2008 Dec 30;88(48):3397-400.

Abstract

OBJECTIVE

To investigate the expression of estrogen receptor (ER), progesterone receptor (PR), and human epithelial growth factor receptor 2 (HER2) in breast cancer, and to explore their correlation with the age of patient, and size, clinic stage, and lymph node metastasis of the tumor.

METHODS

The data of 910 breast cancer, 89.4% of invasive ductal carcinoma, 1.7% of invasive lobular carcinoma, 44 cases 5% of ductal carcinoma in situ, and 4.9% of other pathologic types, 29.9% being less than 2 cm, 45.6% being 2-5 cm, and 24.5% bigger than 5 cm in size, 54.2% without metastasis in lymph node, 25.5% with metastasis in 1-3 lymph nodes, and 20.3% with metastasis in more than 3 lymph nodes respectively, were analyzed retrospectively. Immunohistochemistry was used to detect the expression of ER, PR, and HER2.

RESULTS

The ER negative expression rate was 33.0%, and PR negative expression rate was 27.4%, and HER2 overexpression rate was 20.3%. The possibility of lymph node metastasis decreased along with the increase of age (P < 0.001). Tumor size was negatively correlated with the expression of ER and PR (both P < 0.001), and positively correlated with the expression of HER2 (P < 0.001). There was no significant difference between the situation of lymph node metastasis and the expression of ER, PR and HER2 in primary tumors.

CONCLUSION

As good prognostic markers of breast invasive ductal cancer, ER and PR are negatively correlated with the HER2 expression, as a worse prognostic marker. ER/PR positive or HER2 negative tumors are morel likely to be diagnosed at earlier stages.

摘要

目的

探讨雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HER2)在乳腺癌中的表达情况,并探讨其与患者年龄、肿瘤大小、临床分期及淋巴结转移的相关性。

方法

回顾性分析910例乳腺癌患者的数据,其中浸润性导管癌占89.4%,浸润性小叶癌占1.7%,导管原位癌44例(占5%),其他病理类型占4.9%;肿瘤大小方面,29.9%小于2 cm,45.6%为2 - 5 cm,24.5%大于5 cm;淋巴结转移情况分别为,54.2%无淋巴结转移,25.5%有1 - 3个淋巴结转移,20.3%有3个以上淋巴结转移。采用免疫组织化学法检测ER、PR及HER2的表达。

结果

ER阴性表达率为33.0%,PR阴性表达率为27.4%,HER2过表达率为20.3%。淋巴结转移的可能性随年龄增加而降低(P < 0.001)。肿瘤大小与ER和PR的表达呈负相关(均P < 0.001),与HER2的表达呈正相关(P < 0.001)。原发性肿瘤的淋巴结转移情况与ER、PR及HER2的表达之间无显著差异。

结论

作为乳腺浸润性导管癌的良好预后标志物,ER和PR与作为较差预后标志物的HER2表达呈负相关。ER/PR阳性或HER2阴性的肿瘤更有可能在早期被诊断出来。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验